Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation

被引:0
作者
Ivetta Danylesko
Rina Sareli
Nira Varda-Bloom
Ronit Yerushalmi
Noga Shem-Tov
Hila Magen
Avichai Shimoni
Arnon Nagler
机构
[1] Chaim Sheba Medical Center,The Division of Hematology and Bone Marrow Transplantation
[2] Tel-Hashomer,Sackler Faculty of Medicine
[3] Tel Aviv University,undefined
来源
International Journal of Hematology | 2021年 / 114卷
关键词
Autologous transplantation; Stem cell mobilization; Lipegfilgrastim;
D O I
暂无
中图分类号
学科分类号
摘要
Autologous stem cell transplantation (ASCT) is a standard of care in newly-diagnosed multiple myeloma (MM) patients. Several studies before the introduction of novel therapies in MM, demonstrated a pegylated G-CSF to be successful in mobilizing peripheral blood stem cells (PBSCs). Lipegfilgrastim is a novel long-acting G-CSF that is produced by the conjugation of a single 20-kDa polyethelene glycol to the natural O-glycosylation site of G-CSF. Twenty-four MM patients were included for PBSCs mobilization with a single SC injection of 6 mg lipegfilgrastim. PBSC collection was started when the CD34+ count was > 10 × 106 cells/L. The target progenitor cells were 6 × 106 cells/kg. The median day of apheresis was + 3 (range 2–5) following lipegfilgrastim. Median peripheral blood CD34+ count pre-mobilization was of 22.65 (range 3.36–105) × 106 cells/L. The median number of leukaphaeresis procedures was 2 (range 1–4). The median mobilized CD34+ cells/kg were 8.26 (range 0.77–12.42). One patient failed to mobilize and two patients mobilized < 6 × 106 cells/kg. Toxicity was mild and transient. Twenty-three patients underwent ASCT following high dose melphalan. All patients engrafted. As lipegfilgrastim is administered only once, it is conceivable that it improves both compliance and quality-of-life (NCT02488382).
引用
收藏
页码:363 / 372
页数:9
相关论文
共 295 条
[41]  
Fassas A(2017)Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma Eur J Haematol 98 388-625
[42]  
Takeyama K(2009)Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma Bone Marrow Transplant 43 619-1528
[43]  
Ohto H(2020)CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study Transfusion 60 1519-1056
[44]  
Danylesko I(2008)Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation Biol Blood Marrow Transplant 14 1045-128
[45]  
Sareli R(2014)The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) Crit Rev Oncol Hematol 89 112-35
[46]  
Varda-Bloom N(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29-1311
[47]  
Yerushalmi R(2008)Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings Biol Blood Marrow Trans 14 1305-124
[48]  
Shem-Tov N(2003)Stem cell mobilization by G-CSF in solid and hematological malignancies: single daily dose is better than split dose in obese patients J Clin Apher 18 120-1005
[49]  
Shimoni A(2012)Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF Bone Marrow Trans 47 1003-7091
[50]  
Steinberg M(2005)Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance J Immunol 175 7085-891